- Founded
- 2017
- Employees
- 75
- Total Funding
- $538.5M
Founded by Alan Russell, Badreddin Edris, Peter Thompson in 2017.
About Edgewise Therapeutics
At Edgewise, we are on a mission to discover new medicines that improve the lives of patients facing serious muscle disease. Our intimate knowledge of muscle biology and biophysics along with our ability to identify and design muscle specific precision small molecules have enabled us to rapidly advance our skeletal muscle and cardiac muscle product candidates into the clinic while also building a robust pre-clinical pipeline. With this focus on therapeutics designed to protect and improve muscle health, our goal is to dramatically enhance the lives of people living with progressive muscle disorders.
Leadership at Edgewise Therapeutics
The team at the top of the org chart.
Kevin Koch
President and CEO
85 reports
Mike Carruthers
Chief Financial Officer
5 reports
Nicole Rempel Kilburn
Vice President, Regulatory & Program Management
Zhou Jiang
Vice President Of Early Commercial And Corporate Strategy
1 report
Maureen Franco
VP Corporate Communications
1 report
Joanne Donovan
Chief Medical Officer
2 reports
John Moore
General Counsel
4 reports
Behrad Derakhshan
Chief Operating Officer
1 report
Alan Russell
Co-founder & Chief Scientific Officer
3 reports
Open Jobs at Edgewise Therapeutics (13)
- Edgewise Therapeutics · US · 1mo$225k – $285k
- Edgewise Therapeutics · US · 2mo$90k – $140k
- Edgewise Therapeutics · US · 2mo$170k – $220k
- Edgewise Therapeutics · US · 2mo$170k – $220k
- Edgewise Therapeutics · US · 2mo$170k – $220k
- Edgewise Therapeutics · US · 2mo$275k – $350k
- Edgewise Therapeutics · US · 2mo$130k – $180k
- Edgewise Therapeutics · US · 2mo$135k – $175k
- Edgewise Therapeutics · US · 2mo$240k – $325k
- Edgewise Therapeutics · US · 2mo$170k – $200k
- Edgewise Therapeutics · US · 2mo$135k – $175k
- Edgewise Therapeutics · US · 2mo$230k – $260k
- Edgewise Therapeutics · US · 2mo$120k – $150k